Objective: TGPO autoantibodies (aAbs) that bind simultaneously to thyroglobulin (Tg) and thyroperoxidase (TPO) are present in the serum of patients with autoimmune thyroid diseases (AITD) and have been found to differ from monospecific Tg and TPO aAbs. To obtain further insights on the prevalence defined as the rate of occurrence and significance of TGPO aAbs in a large population, we carried out a collaborative study involving 15 European teams. Methods: Serum samples from 3122 patients with various thyroid and non-thyroid diseases and normal subjects were assayed using a novel TGPO aAb detection kit. This test was designed so that TGPO aAbs are trapped between the Tg-coated solid phase and the soluble TPO labeled with a radioiodinated monoclonal antibody. Results: Only three out of the 220 normal subjects (prevalence of 1.4%) were found to have positive TGPO aAb levels, which were mainly observed in the patients with AITD: the group of patients suffering from Hashimoto's thyroiditis had a TGPO aAb prevalence of 40.5% (n ¼ 437 patients), those with Graves' disease, a prevalence of 34.6% (n ¼ 645) and those with post-partum thyroiditis, 16.0% (n ¼ 243). Among the non-AITD patients with positive TGPO aAb levels, the TGPO aAb prevalence ranged from 20.7% among those with thyroid cancer (n ¼ 246) to 0% among those with toxic thyroid nodules (n ¼ 47). Among the patients with non-thyroid diseases, the TGPO aAb prevalence ranged from 9.8% in the case of Biermer's pernicious anemia (n ¼ 78) to 0% in that of premature ovarian failure (n ¼ 44). It is worth noting that the groups showing the highest TGPO aAb prevalence also contained the patients with the highest TGPO aAb titers. Statistical comparisons between the TGPO aAb prevalences in the various groups showed that TGPO aAb could be used as a parameter to distinguish between the groups of Hashimoto's and Graves' patients and between the women with post-partum thyroiditis and the post-partum women with only Tg and/or TPO aAb established during early pregnancy. Unexpectedly, the correlations between TGPO aAbs and Tg and TPO aAbs were found to depend mainly on the assay kit used. Conclusion: High TGPO aAb titers are consistently associated with AITD but the reverse was not found to be true. TGPO aAbs are a potentially useful tool, however, for establishing Hashimoto's diagnosis, and would be worth testing in this respect with a view to using them for routine AITD investigations.
Introduction
One common feature of autoimmune thyroid disease (AITD) is the frequent presence of autoantibodies (aAbs) directed against thyroglobulin (Tg) and thyroperoxidase (TPO), which are pivotal thyroid-specific molecules for the production of thyroid hormones (1) . Neither Tg nor TPO aAb positive levels distinguish among the various forms of AITD. However, Tg aAbs are instrumental in the follow-up of differentiated thyroid cancers (2) and TPO aAbs are a serological hallmark of AITD (3) . A few years ago, a new category of aAb reacting simultaneously to Tg and TPO, named TGPO aAb, was reported to be present in patients with AITD in addition to monospecific Tg and TPO aAbs (4) (5) (6) . We suggested in addition that TGPO aAbs might be Tg aAbs that share a common interspecies idiotype reacting with TPO (7) . Results obtained with a TGPO monoclonal antibody suggested that this idiotype may carry an internal image of Tg (8) enhancing its putative role in the homeostasis of AITD (7) . In addition, the distribution of TGPO aAbs among patients with various thyroid and autoimmune diseases was studied using a pilot method for measuring TGPO aAbs (9) . The results of this study showed that TGPO aAbs are mainly present in patients with Hashimoto's thyroiditis, a thyroid disease which is difficult to diagnose, but rarely in the other thyroid diseases and non-thyroid autoimmune diseases. Interestingly, it was established that the TGPO aAb level decreased significantly in a subset of Hashimoto's patients after hormone therapy.
The clinical significance and diagnostic usefulness of TGPO aAb levels are still obscure because no large scale clinical studies have been performed so far on this topic. Here we give the results of a collaborative study involving 15 European teams. In this study, a large number of serum samples were assayed using the same kit produced by BRAHMS Diagnostica in Berlin, based on the pilot method previously developed in Marseille (9) , with a view to determining the prevalence of TPGO aAbs, defined as the rate of occurrence of these aAbs among various groups of patients with thyroid and non-thyroid diseases.
Patients and methods

Patients
The patients were subdivided into groups, in line with the World Health Organization classification. Some patients with an atypical or incomplete clinical diagnosis were placed in specific groups called 'undocumented hypothyroidism' and 'undocumented goiter'. The patients in the study included 645 patients with Graves' disease, 437 with Hashimoto's thyroiditis, 246 with thyroid cancer, 243 with post-partum thyroiditis, 115 with toxic multinodular goiter, 108 with undocumented hypothyroidism, 79 with undocumented goiter, 78 with simple goiter, 67 with uninodular goiter, 61 with multinodular goiter, 47 with toxic thyroid nodules, 38 with post-partum Tg and/or positive TPO aAb titers, 29 with thyroid hormone resistance, 19 with De Quervain's thyroiditis and 5 with Riedel's thyroiditis. The patients with other autoimmune diseases were 158 patients with insulin-dependent diabetes mellitus, 78 with Biermer's pernicious anemia, 71 with systemic lupus erythematosus, and 37 with vitiligo. The patients with non-autoimmune diseases were 123 patients with viral hepatitis treated with interferon a (INFa), 69 with breast cancer and 44 with premature ovarian failure. There were also 220 normal subjects, 61 normal postpartum women and 44 normal pregnant women without any previous or present history of thyroid disease.
Tg and TPO aAb assay
Tg and TPO aAb levels were measured with various commercially available kits and in-house methods. These assays were based on different designs and involved the use of various reagents (Table 1) .
TGPO aAb assay
TGPO aAb levels were measured using a research kit (DYNOtest anti-TGPO, BRAHMS Diagnostica, Berlin, Germany) with a sandwich-type RIA design (Fig. 1) . The solid phase consisted of polystyrene tubes coated with highly purified human Tg. The tracer was prepared from 125 I-labeled TPO monoclonal antibody bound to human TPO. This TPO monoclonal antibody was chosen because it does not cross-react with patients' TPO aAbs (10) . Briefly, the assay was started by adding 20 ml of standard or sample and 200 ml of assay buffer to each tube. After a 20 h incubation period on a horizontal shaker at room temperature, the tubes were washed and 200 ml of the tracer solution were added. After being incubated for 2 h on a horizontal shaker at room temperature, the tubes were washed and the radioactivity of each tube was measured in a gamma counter. The radioactivity measured was directly proportional to the TGPO aAb concentration of the respective samples. In parallel, measured standards were used to determine the concentration of the unknown samples. The TGPO aAb titer (U/ml) was defined arbitrarily using an internal reference standard aAb preparation.
Statistical analysis
The TGPO aAb prevalences among the various groups of subjects and patients were analyzed using an extended x 2 test, and the correlations between TGPO aAb titer and Tg and TPO aAb titers were computed using a commercial software program (Statview 4, Abacus Concepts Inc., Berkeley, CA, USA).
Results
Assay performance
Using the BRAHMS test-kit components, we obtained a dose-response curve in the 10-10 000 U/ml range (Fig. 2) . The maximum binding range was obtained at 14-18% of the total radiolabeled tracer added, and the non-specific binding was consistently less than 0.2%. The functional assay sensitivity (coefficient of variation ¼ 20%), calculated from ten independent inter-assay determinations with native sera, was found to be 30 U/ml. Previous tests showed that the TGPO aAb titer in normal subjects (n ¼ 139) was consistently less than 30 U/ml. Among the selected patients pre-screened to determine their Tg aAb levels (n ¼ 50), 28% were found to have TGPO aAb levels above 30 U/ml, and the mean value obtained was 122.2 U/ml TGPO aAb. The specificity of the TGPO aAb assay was confirmed by the ability of soluble Tg and TPO (10 ¹7 mol/l) to abolish completely the TGPO aAb activity of the positive sera (data not shown).
TGPO aAb assay on normal subjects and patients
The TGPO aAb prevalence in the various groups of normal subjects and patients, is listed in Table 2 in decreasing order. The highest rates were obtained in groups of patients with a well-defined AITD (Hashimoto's thyroiditis: 40.5%; Graves' disease: 34.6%). The rates then decreased from 23.1% to 0% in the case of the other thyroid diseases. One unexpected result was the prevalence of TGPO aAbs in patients with thyroid cancer and thyroid hormone resistance (20.7 and 17.2%, respectively). The 10-2.7% range included groups of patients with various non-thyroid diseases including organ-specific and systemic autoimmune diseases (Biermer's pernicious anemia: 9.8%; viral hepatitis treated with INFa: 7.3%; systemic lupus erythematosus: 4.2%; insulin-dependent diabetes mellitus: 3.2%; breast cancer: 2.9%; vitiligo: 2.7%). The group of normal pregnancy had a low TGPO aAb prevalence (2.2%). Only 1.4% of the 220 normal subjects screened had a positive TGPO aAb titer. The TGPO aAb prevalences were negative in patients with toxic thyroid nodule, De Quervain's and Riedel's thyroiditis and premature ovarian failure.
The distribution of TGPO titers among the various groups of thyroid diseases is shown in Fig. 3 . The highest TGPO aAb titers (>100 U/ml) were obtained in the groups of patients with the highest prevalence (>10%). The corresponding patients displayed an overt AITD such as Hashimoto's or Graves' disease. It seems likely that many patients with undocumented hypothyroidism suffer from AITD. On the other hand, the lowest titers corresponded to patients from non-AITD groups in which the TGPO aAb prevalence was low. One exception was the group of women with postpartum thyroiditis, which had a high prevalence (16.0%), although the corresponding patients had low TGPO aAb titers.
Clinical significance of the TGPO aAb assay
To evaluate the diagnostic value of TGPO aAb measurements, we carried out statistical comparisons between the positive TGPO aAb ratios of various groups, taken two by two, in the population with a TGPO aAb prevalence greater than 10%. As can be seen from Fig. 4 , the TGPO aAb prevalence in the group of patients with Hashimoto's thyroiditis was statistically different from those measured in the other groups, except for women with post-partum thyroiditis. The TGPO aAb prevalence observed in the group of Graves' patients was not statistically different from that of the groups with post-partum thyroiditis and thyroid hormone Table 2 ). The cut-off value (30 U/ml) is indicated by the dashed line.
V Estienne and others
EUROPEAN JOURNAL OF ENDOCRINOLOGY (1999) 141
resistance. In the latter group, however, the Tg and TPO aAb titers were generally high and very low, respectively. Contrary to what was observed in the case of postpartum thyroiditis, the group of post-partum patients with only Tg and/or TPO aAb differed from the group of patients with overt AITD.
Relationships between TGPO aAbs and Tg and TPO aAbs
The ratio between patients with positive TGPO and negative Tg or TPO aAb titers varied considerably from 0 to 52.3% in the case of Tg aAbs (Table 3) and from 0 to 30.2% in that of TPO aAbs (Table 4) , depending on the kit used. By contrast, when kits from the same manufacturer (BRAHMS Diagnostica) were used, several groups showed far less variation (0-4.5% in the case of Tg aAbs and 0-7.5% in that of TPO aAbs). The correlation between TGPO, Tg and TPO aAb titers also varied from one kit to another. The TGPO and Tg aAb titers were significantly correlated in 8 out of the 11 groups. Upon comparing the TGPO and TPO aAb titers, a significant correlation was observed in only 3 out of the 12 groups. As above, the 
Figure 4
Criss-cross comparisons between the TGPO aAb prevalence in various groups of thyroid diseases. The squares on the diagonal line indicate no statistical difference between TGPO aAb prevalence (white square). Black square indicates a statistically significant difference with P < 0.05. groups with kits from the same manufacturer yielded similar results. One interesting outcome of this study emerged upon making indirect comparisons between the various Tg and TPO aAb kits. Five out of the 10 different Tg aAb kits used differed from the others in terms of the high percentage (>10%) of patients with positive TGPO and negative Tg aAb titers and/or the absence of any correlation between TGPO and Tg aAb titers (P < 0.05). By contrast, an unexpected correlation was found to exist between TGPO and TPO aAb titers with three out of the nine different TPO aAb kits, one of which gave a high percentage (30.2%) of patients with positive TGPO but not TPO aAb titers. All in all, these results seem to suggest that some Tg and TPO aAb kits suffer from a lack of sensitivity and/or specificity.
Discussion
In the present study, a commercial kit designed for the measurement of TGPO aAb levels was used. This assay method was slightly modified in comparison with the original method described in a previous study (9) . It was found to be a strictly specific method of detecting TGPO aAbs, and to be sensitive and reliable, and therefore suitable for use in routine clinical testing.
TGPO aAbs are mainly present in patients with AITD. They occur frequently in patients with thyroid cancer and thyroid hormone resistance, and much less frequently in patients with simple goiter and toxic multinodular goiter, presumably indicating the presence of silent AITD. It is worth noting, however, that in the case of non-AITD, the TGPO aAb titers are frequently in the range of the threshold value. It might be worth reassessing the cut-off titer at which positivity can be said to be present, in order to obtain more clear cut results. Measuring TGPO aAb levels seems to be a useful means of distinguishing between groups of Hashimoto's and Graves' patients and between groups of women with post-partum thyroiditis and post-partum women with only positive Tg and/or TPO aAb titers in early pregnancy. Longitudinal studies may be necessary to elucidate the pathological significance and diagnostic value of the TGPO aAb assay.
In an initial clinical study, a correlation was found to exist between TGPO and Tg but not TPO aAb titers (9) . These results were taken to reflect the existence of a similar pattern of aAb heterogeneity in the Tg and TGPO aAb populations recognizing Tg epitopic sites. By contrast, they were indicative of a difference in the aAb heterogeneity between the TPO and TGPO aAb populations recognizing TPO epitopic sites, which might be attributable to the fact that TGPO aAbs bound to TPO via a specific idiotype (7). The results obtained in this study with most of the Tg and TPO kits used are in agreement with those obtained in the previous study (9) . Unfortunately, the differences observed between the Tg and TPO aAb measurements obtained with the various manufacturer's kits made it impossible to perform overall statistical comparisons between the Tg and TPO aAb prevalence relative to that of TGPO aAb. This indirectly highlights the recurrent problem concerning the need to standardize materials and methods for aAb measurement.
The presence of TPO aAbs is more indicative of AITD than the presence of Tg aAbs (11) and, as shown in this study, the presence of TGPO aAbs can be used to distinguish between Hashimoto's, Graves' and postpartum thyroid diseases. We therefore propose the TPO and TGPO aAb titers as the measured parameters on which AITD diagnosis should henceforth be based.
